Nirmatrelvir-ritonavir may lower risk of intubation or in-hospital mortality in patients with severe COVID-19.
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no ...
A new study published in the journal of The Lancet Infectious Diseases showed that an efficient substitute for current COVID-19 therapies is ensitrelvir, a once-daily oral SARS-CoV-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results